Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.

Dae Ho LeeHye Ryun KimBhumsuk KeamKen KatoYasutoshi KubokiHaiyan GaoAlejandro YovineScott H RobbinsMyung-Ju Ahn

Published in: Cancer medicine (2023)

Durvalumab with tremelimumab and chemotherapy demonstrated manageable safety and antitumor activity in patients with advanced or metastatic ESCC, warranting further investigation in randomized trials. Registered with ClinicalTrials.gov: NCT02658214.

Keyphrases

locally advanced
squamous cell carcinoma
small cell lung cancer
open label
radiation therapy
rectal cancer